000119315 001__ 119315
000119315 005__ 20240228145432.0
000119315 0247_ $$2doi$$a10.1080/0284186X.2016.1266089
000119315 0247_ $$2pmid$$apmid:28055266
000119315 0247_ $$2ISSN$$a1100-1704
000119315 0247_ $$2ISSN$$a1651-226X
000119315 0247_ $$2ISSN$$a1651-2499
000119315 037__ $$aDKFZ-2017-00070
000119315 041__ $$aeng
000119315 082__ $$a610
000119315 1001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b0$$eFirst author$$udkfz
000119315 245__ $$aQuality of life in long-term and very long-term cancer survivors versus population controls in Germany.
000119315 260__ $$aAbingdon$$bTaylor & Francis Group$$c2017
000119315 3367_ $$2DRIVER$$aarticle
000119315 3367_ $$2DataCite$$aOutput Types/Journal article
000119315 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1663664655_5887
000119315 3367_ $$2BibTeX$$aARTICLE
000119315 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119315 3367_ $$00$$2EndNote$$aJournal Article
000119315 500__ $$a2017 Feb;56(2):190-197
000119315 520__ $$aWith the increasing number and diversity of cancer survivors, studies of survivors' physical, emotional, and social health are of growing importance. While there is a growing body of literature on the quality of life (QoL) of cancer patients during the early years past diagnosis, less is known regarding QoL in long-term survivors (LTS) (5 + years past diagnosis) and particularly in very long-term survivors (VLTS) (10 + years past diagnosis). The objective of our study is to: (1) compare QoL of long-term cancer survivors and population norms; and (2) assess whether any deficits in QoL of survivors observed 5-10 years past diagnosis persist beyond the 10th year past diagnosis.In total 6952 long-term cancer survivors (5-16 years past diagnosis of breast, colorectal, or prostate cancer) from Germany recruited in the context of the population-based CAESAR + study were compared with 1878 population-based controls without a history of cancer. QoL was assessed with the EORTC QLQ-C30. Differences in QoL between survivors and controls were assessed via multiple regression while controlling for age, gender, education, and case mix for survivors 5-9 years and 10 + years past diagnosis separately.Overall QoL in long-term cancer survivors was comparable to population norms but specific deficits in social, role, emotional, cognitive, and physical functioning and symptoms such as insomnia, fatigue, dyspnea, constipation, diarrhea, and financial difficulties were more prevalent in LTSs. Detriments in QoL persisted during the observation period and affected particularly cancer survivors at younger ages (<50 years). Non-significant aggravations in QoL with longer time since diagnosis were observed in very young and very old cancer survivors.Detriments in health-related quality of life persist over more than a decade and affect predominantly younger patients. Improvements both in early and long-term follow-up care of cancer survivors seem warranted.
000119315 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000119315 588__ $$aDataset connected to CrossRef, PubMed,
000119315 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b1$$udkfz
000119315 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b2$$udkfz
000119315 7001_ $$aBertram, Heike$$b3
000119315 7001_ $$aEberle, Andrea$$b4
000119315 7001_ $$0P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aHolleczek, Bernd$$b5$$udkfz
000119315 7001_ $$aSchmid-Höpfner, Sieglinde$$b6
000119315 7001_ $$aWaldmann, Annika$$b7
000119315 7001_ $$aZeissig, Sylke Ruth$$b8
000119315 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$eLast author$$udkfz
000119315 773__ $$0PERI:(DE-600)1492623-4$$a10.1080/0284186X.2016.1266089$$gp. 1 - 8$$n2$$p190-197$$tActa oncologica$$v56$$x0284-186X$$y2017
000119315 909CO $$ooai:inrepo02.dkfz.de:119315$$pVDB
000119315 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119315 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119315 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119315 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000119315 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000119315 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000119315 9141_ $$y2017
000119315 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119315 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119315 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119315 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000119315 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000119315 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-30$$wger
000119315 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA ONCOL : 2019$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000119315 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-30
000119315 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000119315 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000119315 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x2
000119315 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000119315 980__ $$ajournal
000119315 980__ $$aVDB
000119315 980__ $$aI:(DE-He78)C070-20160331
000119315 980__ $$aI:(DE-He78)G110-20160331
000119315 980__ $$aI:(DE-He78)C071-20160331
000119315 980__ $$aI:(DE-He78)L101-20160331
000119315 980__ $$aUNRESTRICTED